Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Sep 9:8:60.
doi: 10.1186/1471-2288-8-60.

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions

Affiliations
Comparative Study

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions

Anders W Jørgensen et al. BMC Med Res Methodol. .

Abstract

Background: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support.

Methods: We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses according to the type of support in 3 categories: industry-supported, non-profit support or no support, and undeclared support.

Results: We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11 undeclared support. On a 0-7 scale, the median quality score was 6 for meta-analyses with non-profit or no support and 2.5 for the industry-supported meta-analyses (P < 0.01). Compared with industry-supported meta-analyses, more meta-analyses with non-profit or no support avoided bias in the selection of studies (P = 0.01), more often stated the search methods used to find studies (P = 0.02), searched comprehensively (P < 0.01), reported criteria for assessing the validity of the studies (P = 0.02), used appropriate criteria (P = 0.04), described methods of allocation concealment (P = 0.05), described methods of blinding (P = 0.05), and described excluded patients (P = 0.08) and studies (P = 0.15). Forty percent of the industry-supported meta-analyses recommended the experimental drug without reservations, compared with 22% of the meta-analyses with non-profit or no support (P = 0.57).In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied that they had not received industry funding were added to those with non-profit or no support, and 3 who did not reply were added to those with industry support. This analysis did not change the results much.

Conclusion: Transparency is essential for readers to make their own judgment about medical interventions guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than meta-analyses with non-profit support or no support.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Search for meta-analyses and reasons for exclusion.

Similar articles

Cited by

References

    1. Stinson ER, Mueller DA. Survey of health professionals' information habits and needs. JAMA. 1980;243:140–3. doi: 10.1001/jama.243.2.140. - DOI - PubMed
    1. Cook DJ, Mulrow CD, Haynes RB. Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions. Ann Intern Med. 1997;126:376–80. - PubMed
    1. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334–6. doi: 10.1136/bmj.323.7308.334. - DOI - PMC - PubMed
    1. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsored and research outcome and quality: systematic review. BMJ. 2003;326:1167–70. doi: 10.1136/bmj.326.7400.1167. - DOI - PMC - PubMed
    1. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454–65. doi: 10.1001/jama.289.4.454. - DOI - PubMed

LinkOut - more resources